- “There have been several changes in the listing sector.”
- Founded in 2001, sinobio is a first-class international enterprise specializing in the large-scale production of peptide and amino acid drugs.
- It is worth mentioning that among the shareholders of sinobio, Lepu medical (300003. SZ) also appeared. According to tianyancha, Lepu medical contributed 5.4 million yuan to hold 9%, which is the second largest shareholder of the company.
- For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
“There have been several changes in the listing sector.”
Author Pang Shifan
According to the IPO news, Chengdu Shengnuo Biotechnology Co., Ltd. recently submitted an application for change of guidance and filing. It plans to change the listing board from the growth enterprise board to the science and technology innovation board, and the guidance institution is Minsheng securities.
Founded in 2001, sinobio is a first-class international enterprise specializing in the large-scale production of peptide and amino acid drugs.
Its total assets have reached 250 million. At present, it has more than 50 key technologies for large-scale peptide production at home and abroad, and 0 defect has passed the FDA certification. It has undertaken the national 11th five year plan major new drug development and research project, and has been awarded the titles of “national high-tech enterprise”, “Sichuan enterprise technology center”, “Chengdu peptide drug engineering technology research center”.
Therefore, in May last year, the company started to prepare for listing in the shengnuo biological change board. It originally applied for listing in the small and medium-sized board or the growth enterprise board to change to the science and technology innovation board. In the same month, it obtained the equity investment of Dachen venture capital. But just a week before the start of the science and technology innovation board, it said that according to the needs of the company’s development, it would be transferred back to the Shenzhen Stock Exchange gem for listing. This is the third time that sanuo biology has adjusted its listing plate.
It is worth mentioning that among the shareholders of sinobio, Lepu medical (300003. SZ) also appeared. According to tianyancha, Lepu medical contributed 5.4 million yuan to hold 9%, which is the second largest shareholder of the company.
Sanuobio mainly develops and produces APIs and polypeptide drug preparations, which are applied to autoimmune diseases, HIV-1 infected patients, etc. in addition, the company also provides professional polypeptide drug research and development services, and undertakes domestic and foreign polypeptide projects, especially cro of innovative polypeptide projects/ C (d) Mo business can produce 1.5 tons of peptide API, 400 million tablets (granules) of solid preparation, 36 million bottles of freeze-dried powder injection and small volume injection, 5 million pre filled injection and 5 million cartridge injection annually.
At present, it has successfully realized the industrialization transformation of several new peptide drugs for Chengdu Di’ao, Zhejiang Haizheng, Harbin Pharmaceutical Group, Hainan Zhonghe, frontier Biology (Nanjing).
The wholly-owned subsidiary of sinobio, including Chengdu sinobio Pharmaceutical Co., Ltd., has also achieved commercial production. A number of peptide API production workshops have passed the official GMP certification of China, the United States, South Korea and Mexico.
A number of foreign brands of peptide drugs, such as Novartis Pharmaceutical Co., Ltd. and xuelanuo Co., Ltd., have been successfully imported into China, but at present, China’s peptide drug industry is still in its infancy and growth stage.
Although the “global new” peptide molecule is in its infancy in China, innovative drugs are catching up with the “Dongfeng” of deepening the reform of the drug review and approval system. Products with clear clinical efficacy that are not listed in China and abroad will accelerate to market.
In 2016, the first domestic generic and independent intellectual property rights carbetoxine API and carbetoxine injection produced by Suntory bio were approved and listed, and three of several products under research submitted listing applications, including the generic drug of lilalutide injection.
Lilaluptide injection is the only GLP-1 analog in the current medical insurance catalog. In 2018, the global sales volume was US $4.468 billion, ranking first in the sales volume of diabetes drugs overseas. The sales volume of lilaluptide injection in the terminals of public medical institutions in China was nearly RMB 500 million, up nearly 50% year on year.
However, domestic generic pharmaceutical enterprises are hard to produce for a long time. The domestic market of lilaluptide is monopolized by the original manufacturer Novo Nordisk. Sanuobio will apply for registration according to the new four categories of chemical drugs. If the application is successful, it will have a huge market share. In addition, it is reported that sanuobio is a raw material supplier of lilaluptide DMF in the United States. Sanuobio said that the company also has a large mass production cost advantage.
Disclaimer: This article is from Tencent News client self media and does not represent Tencent’s views and positions.
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.